US Stock MarketDetailed Quotes
RARE Ultragenyx Pharmaceutical
- 50.470
- +6.320+14.31%
Close Aug 2 16:00 ET
- 47.000
- -3.470-6.88%
Pre 08:20 ET
4.65BMarket Cap-7000P/E (TTM)
50.750High44.230Low2.70MVolume47.200Open44.150Pre Close130.96MTurnover3.28%Turnover RatioLossP/E (Static)92.17MShares54.56052wk High10.76P/B4.16BFloat Cap31.52052wk Low--Dividend TTM82.33MShs Float179.647Historical High--Div YieldTTM14.77%Amplitude31.520Historical Low48.565Avg Price1Lot Size
About Ultragenyx Pharmaceutical Company
Ultragenyx Pharmaceutical, Inc. engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010, and is headquartered in Novato, CA.
Company Profile
SymbolRARE
Company NameUltragenyx Pharmaceutical
Listing DateJan 31, 2014
Issue Price21.00
Founded2010
CEODr. Emil D. Kakkis, M.D.,PhD
MarketNASDAQ
Employees1276
Securities TypeOrdinary Shares
Fiscal Year Ends12-31
Address60 Leveroni Court
CityNovato
ProvinceCalifornia
CountryUnited States of America
Zip Code94949
Phone1-415-483-8800
Websitehttp://www.ultragenyx.com
Company Executives
- Name
- Position
- Salary
- Dr. Emil D. Kakkis, M.D.,PhD
- Director, President, Chief Executive Officer
- 13.08M
- Karah Parschauer
- Chief Legal Officer and Executive Vice President, Corporate Affairs
- 4.04M
- Thomas R. Kassberg
- Chief Business Officer and Executive Vice President
- --
- John Richard Pinion, II
- Chief Quality Officer and Executive Vice President, Translational Sciences
- 4.05M
- Erik Harris
- Chief Commercial Officer and Executive Vice President
- 4.07M
- Dr. Eric Crombez, M.D.
- Executive Vice President and Chief Medical Officer
- --
- Howard Horn
- Chief Financial Officer and Executive Vice President, Corporate Strategy
- 5.94M
- Theodore A. Huizenga
- Senior Vice President, Corporate Controller and Chief Accounting Officer
- --
- Dennis Karl Huang
- Chief Technical Operations Officer and Executive Vice President, Gene Therapy Operations
- --
- Daniel G. Welch
- Chairman of the Board
- 499.89K
- Matthew K. Fust
- Independent Director
- 479.89K
- Dr. Deborah L. Dunsire,M.D.
- Independent Director
- 459.89K
- Dr. Shehnaaz Suliman, M.D.
- Independent Director
- 466.89K
- Michael A. Narachi
- Independent Director
- 482.39K
- Dr. Corazon Dating Sanders, PhD
- Independent Director
- 469.39K
- Dr. Amrit Ray, M.D.
- Independent Director
- 460.39K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
